Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P180031/S012

Neuroform Atlas Stent System

Stryker Neurovascular · Decision date Oct 24, 2026

MEDTECHLEDGER EXPLANATIONP180031/S012

What did the FDA approve?

FDA approved supplement S012 to PMA P180031 for the Neuroform Atlas Stent System on October 24, 2026. The supplement covers a manufacturing site at Nitinol Devices and Components Costa Rica, S.R.L., Building B28, El Coyol, Alajuela 20102 Costa Rica, for postlaser cutting operations of the Neuroform Atlas stent component.

This is a location change for a manufacturer, not a new approval of the whole system. The stated scope is limited to postlaser cutting operations at the named Costa Rica site. The source statement does not describe any change to indications, labeling, design, or clinical data, and it does not provide evidence of safety or effectiveness beyond the administrative approval record.

FDA approval order statement

approval for a manufacturing site located at Nitinol Devices and Components Costa Rica, S.R.L., Building B28, El Coyol, Alajuela 20102 Costa Rica for the postlaser cutting operations of the Neuroform Atlas stent component
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Neurology
Decision date
Oct 24, 2026
FDA change category
Location Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P180031/S012
Regulatory pathway
PMA supplement
Product code
QCA
Decision code
APPR
Decision date
Oct 24, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Intracranial coil-assist stent.

Product code
QCA
FDA device class
3

For the original device and its historical approval scope, see PMA P180031. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P180031 · Original PMA

    Neuroform Atlas Stent System

  2. P180031/S012 received

    Application receipt date recorded by FDA.

  3. P180031/S012 · FDA decision

    Normal 180 Day Track No User Fee

Timeline entries are records held by MedtechLedger for P180031. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P180031

Product / regulatory recordCompanyPathwayDecision dateSource
Stryker NeurovascularPMA approvalMay 16, 2019FDA

Explore the linked device profile

Other records with product code QCA

Product / regulatory recordCompanyPathwayDecision dateSource
Microvention, Inc.PMA supplementSep 16, 2026FDA
Microvention, Inc.PMA approvalMay 30, 2018FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Stryker Neurovascular

Headquarters
Not reported
Brand website
stryker.com
FDA applicant address
47900 Bayside Pkwy., Fremont, CA, 94538

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records